Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 7/20 | 0.57 |
| ▸ | MAOA | P21397 | 4/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.57 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.57 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.57 |
| ▸ | ACHE | P22303 | 1/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.55 |
| ▸ | HPGD | P15428 | 6/20 | 0.53 |
| ▸ | MCL1 | Q07820 | 4/20 | 0.53 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.53 |
| ▸ | THRB | P10828 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 3/20 | 0.50 |
| ▸ | CA12 | O43570 | 2/20 | 0.50 |
| ▸ | GLA | P06280 | 2/20 | 0.50 |
| ▸ | CASP1 | P29466 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9361777 | 0.81 | ALDH1A1 (0.56) | KDM4EALDH1A1HSD17B10MAOACYP3A4 | |
| SCHEMBL28145934 | 0.81 | MAOA (0.54) | KDM4EALDH1A1HSD17B10MAOACYP3A4 | |
| SCHEMBL23640376 | 0.80 | KDM4E (0.57) | KDM4EALDH1A1HSD17B10MAOACYP3A4 | |
| SCHEMBL8440887 | 0.80 | PTPN1 (0.53) | KDM4EALDH1A1HSD17B10MAOACYP3A4 | |
| SCHEMBL6994969 | 0.78 | ALDH2 (0.56) | KDM4EALDH1A1HSD17B10MAOACYP3A4 | |
| SCHEMBL18073930 | 0.76 | AKR1B1 (0.61) | KDM4EALDH1A1HSD17B10MAOACYP3A4 | |
| SCHEMBL28145932 | 0.76 | MCL1 (0.58) | KDM4EALDH1A1HSD17B10MAOACYP3A4 | |
| SCHEMBL9245259 | 0.76 | KDM4E (0.57) | KDM4EALDH1A1HSD17B10MAOACYP3A4 | |
| SCHEMBL599471 | 0.76 | KDM4E (0.57) | KDM4EALDH1A1HSD17B10MAOACYP3A4 | |
| SCHEMBL20278636 | 0.74 | MAOA (0.55) | KDM4EALDH1A1HSD17B10MAOACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 165 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9309315-B2 | Therapy with CD4 binding peptides and radiation | GENMAB A/S (DK) | 2016-04-12 | — | — | US | claimed |
| EP-1951303-B1 | THERAPY WITH ANTI-CD4 ANTIBODIES AND RADIATION | GENMAB AS (DK) | 2011-02-02 | — | — | EP | claimed |
| US-20100015134-A1 | Therapy With CD4 Binding Peptides and Radiation | GENMAB A/S | 2010-01-21 | — | — | US | claimed |
| EP-1951303-A2 | THERAPY WITH CD4 BINDING PEPTIDES AND RADIATION | Genmab A/S (DK) | 2008-08-06 | — | — | EP | claimed |
| WO-2007019865-A2 | THERAPY WITH CD4 BINDING PEPTIDES AND RADIATION | GENMAB A/S (DK) | 2007-02-22 | — | — | WO | claimed |
| US-20060252674-A1 | Methods for pretreating a subject with extracorporeal photopheresis | THERAKOS, INC. | 2006-11-09 | — | — | US | claimed |
| EP-1674095-A1 | Phototherapy compositions | OMJ Ireland Limited (PR) | 2006-06-28 | — | — | EP | claimed |
| US-20060134031-A1 | Phototherapy compositions and methods | MALLINCKRODT ENTERPRISES LLC | 2006-06-22 | — | — | US | claimed |
| EP-0579784-B1 | METHOD FOR PREVENTING RESTENOSIS FOLLOWING RECONFIGURATION OF BODY VESSELS | ADVANCED RES & TECH INST (US) | 1999-11-10 | — | — | EP | claimed |
| EP-0661920-B1 | THE USE OF PSORALEN COMPOUNDS TO INHIBIT RESTENOSIS FOLLOWING ANGIOPLASTY | BISACCIA EMIL (US) | 1999-04-14 | — | — | EP | claimed |
| US-5426116-A | Photophoresis methods for treating atherosclerosis and for preventing restenosis following angioplasty | BISACCIA & KLAINER, INC. (US) | 1995-06-20 | — | — | US | claimed |
| US-5284869-A | Photophoresis methods for treating atherosclerosis and for preventing restenosis following angioplasty | BISACCIA & KLAINER, INC. | 1994-02-08 | — | — | US | claimed |
| US-5219882-A | Treatment methods for lymes disease and associated debilitating conditions | BISACCIA EMIL (US) | 1993-06-15 | — | — | US | claimed |
| EP-0453497-A4 | TREATMENT METHODS AND VACCINES | — | 1992-10-07 | — | — | EP | claimed |
| US-5116864-A | Method for preventing restenosis following reconfiguration of body vessels | INDIANA UNIVERSITY FOUNDATION (US) | 1992-05-26 | — | — | US | claimed |
| EP-0453497-A1 | TREATMENT METHODS AND VACCINES | BISACCIA, Emil (US) | 1991-10-30 | — | — | EP | claimed |
| US-4960408-A | ADMINISTERING A PSORALEN COMPOUND, EXPOSING TO ELECTROMAGNETIC RADIATION | KLAINER ALBERT S (US) | 1990-10-02 | — | — | US | claimed |
| WO-1990007952-A1 | TREATMENT METHODS AND VACCINES | BISACCIA EMIL (US) | 1990-07-26 | — | — | WO | claimed |
| US-4748120-A | Photochemical decontamination treatment of whole blood or blood components | DIAMOND SCIENTIFIC CO. (US) | 1988-05-31 | — | — | US | claimed |
| US-20250177534-A1 | THERMOSTABLE UV INACTIVATED VACCINES AND OTHER BIOPHARMACEUTICALS | UNIVERSAL STABILIZATION TECHNOLOGIES INC. (US) | 2025-06-05 | — | — | US | disclosed |
| WO-2023164075-A1 | THERMOSTABLE UV INACTIVATED VACCINES AND OTHER BIOPHARMACEUTICALS | UNIVERSAL STABILIZATION TECHNOLOGIES INC. (US) | 2023-08-31 | — | — | WO | disclosed |
| US-20220168411-A1 | PSORALEN-INACTIVATED CORONAVIRUS VACCINE AND METHOD OF PREPARATION | THE UNITED STATES OF AMERICAN AS REPRESENTED BY THE SECRETARY OF THE NAVY (US) | 2022-06-02 | — | — | US | disclosed |
| US-20210388318-A1 | USE OF APOPTOTIC CELLS EX VIVO TO GENERATE REGULATORY T CELLS | MALLINCKRODT LLC | 2021-12-16 | — | — | US | disclosed |
| US-10556055-B2 | Method for collecting a desired blood component and performing a photopheresis treatment | Mallinckrodt Hospital Products IP Limited (IE) | 2020-02-11 | — | — | US | disclosed |
| EP-1512418-B2 | Peristaltic pump apparatus for an extracorporeal blood circuit | THERAKOS INC (US) | 2019-08-14 | — | — | EP | disclosed |
| US-10138464-B2 | Use of apoptotic cells ex vivo to generate regulatory T cells | Mallinckrodt Hospital Products IP Limited (IE) | 2018-11-27 | — | — | US | disclosed |
| EP-2008676-B1 | Blood separation apparatus | THERAKOS INC (US) | 2018-06-20 | — | — | EP | disclosed |
| US-20180071451-A1 | METHOD FOR COLLECTING A DESIRED BLOOD COMPONENT AND PERFORMING A PHOTOPHERESIS TREATMENT | OCERA THERAPEUTICS LLC | 2018-03-15 | — | — | US | disclosed |
| EP-2443922-B1 | The use of apoptotic cells ex vivo to generate regulatory T cells | THERAKOS INC (US) | 2017-05-03 | — | — | EP | disclosed |
| CN-106565734-A | Psoralen ester derivatives and applications thereof | 中国科学院新疆理化技术研究所 | 2017-04-19 | — | — | CN | disclosed |
| US-20160235708-A1 | TOPICAL PIGMENTORY COMPOSITION | BANERJI SANJAY (IN) | 2016-08-18 | — | — | US | disclosed |
| US-9309315-B2 | Therapy with CD4 binding peptides and radiation | GENMAB A/S (DK) | 2016-04-12 | — | — | US | disclosed |
| US-20160046909-A1 | Use of Apoptotic Cells Ex Vivo to Generate Regulatory T Cells | MALLINCKRODT ENTERPRISES LLC | 2016-02-18 | — | — | US | disclosed |
| WO-2015049694-A9 | TOPICAL PIGMENTORY COMPOSITION | BANERJI SANJAY (IN) | 2016-02-04 | — | — | WO | disclosed |
| US-9169461-B2 | Use of apoptotic cells ex vivo to generate regulatory T cells | THERAKOS, INC. (US) | 2015-10-27 | — | — | US | disclosed |
| US-20150291936-A1 | PSORALEN-INACTIVATED DENGUE VIRUS VACCINE AND METHOD OF PREPARATION | THE UNITED STATES OF AMERICAN AS REPRESENTED BY THE SECRETARY OF THE NAVY (US) | 2015-10-15 | — | — | US | disclosed |
| EP-2913052-A1 | Phototherapy compositions and methods | OMJ Ireland Limited (PR) | 2015-09-02 | — | — | EP | disclosed |
| EP-2896418-A1 | Method for collecting a desired blood component and performing a photopheresis treatment | THERAKOS, INC. (US) | 2015-07-22 | — | — | EP | disclosed |
| US-9005633-B2 | Psoralen-inactivated viral vaccine and method of preparation | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE NAVY. (US) | 2015-04-14 | — | — | US | disclosed |
| WO-2015049694-A1 | TOPICAL PIGMENTORY COMPOSITION | BANERJI SANJAY (IN) | 2015-04-09 | — | — | WO | disclosed |
| EP-1512421-B1 | Method for collecting a desired blood component and performing a photopheresis treatment | THERAKOS INC (US) | 2014-12-24 | — | — | EP | disclosed |
| US-8481008-B2 | Phototherapy compositions and methods | THERAKOS, INC. (US) | 2013-07-09 | — | — | US | disclosed |
| EP-2527838-A2 | Methods and reagents for detecting susceptibility to transplant related mortality (TRM) | THERAKOS, INC. (US) | 2012-11-28 | — | — | EP | disclosed |
| EP-2527458-A2 | Methods and reagents for detecting susceptilbility to graft versus host disease | THERAKOS, INC. (US) | 2012-11-28 | — | — | EP | disclosed |
| EP-2527839-A2 | Methods and reagents for detecting susceptilbility to transplant related mortality | THERAKOS, INC. (US) | 2012-11-28 | — | — | EP | disclosed |
| EP-2527840-A2 | Methods and reagents for detecting susceptilbility to graft versus host disease | THERAKOS, INC. (US) | 2012-11-28 | — | — | EP | disclosed |
| EP-2443922-A1 | The use of apoptotic cells ex vivo to generate regulatory T cells | THERAKOS, INC. (US) | 2012-04-25 | — | — | EP | disclosed |
| US-20120039825-A1 | PHOTOTHERAPY COMPOSITIONS AND METHODS | MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED (IE) | 2012-02-16 | — | — | US | disclosed |
| US-8057785-B2 | Phototherapy compositions and methods | OMJ IRELAND LIMITED (US) | 2011-11-15 | — | — | US | disclosed |
| US-20110171664-A1 | METHODS AND REAGENTS FOR DETECTING SUSCEPTIBILITY TO GRAFT VERSUS HOST DISEASE OR TRANSPLANT RELATED MORTALITY | O'BRIEN PETER J | 2011-07-14 | — | — | US | disclosed |
| US-7914477-B2 | Apparatus for the continuous separation of biological fluids into components and method of using same | THERAKOS, INC. (US) | 2011-03-29 | — | — | US | disclosed |
| EP-1550454-B1 | Extracorporeal photopheresis in combination with anti-TNF treatment | THERAKOS INC (US) | 2011-03-09 | — | — | EP | disclosed |
| EP-1951303-B1 | THERAPY WITH ANTI-CD4 ANTIBODIES AND RADIATION | GENMAB AS (DK) | 2011-02-02 | — | — | EP | disclosed |
| US-20110014233-A1 | PSORALEN-INACTIVATED VIRAL VACCINE AND METHOD OF PREPARATION | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE NAVY | 2011-01-20 | — | — | US | disclosed |
| US-7850634-B2 | Method for collecting a desired blood component and performing a photopheresis treatment | THERAKOS, INC. (US) | 2010-12-14 | — | — | US | disclosed |
| US-20100015134-A1 | Therapy With CD4 Binding Peptides and Radiation | GENMAB A/S | 2010-01-21 | — | — | US | disclosed |
| EP-1512418-B1 | Peristaltic pump apparatus for an extracorporeal blood circuit | THERAKOS INC (US) | 2009-10-28 | — | — | EP | disclosed |
| EP-1674120-B1 | Apparatus for collecting a blood component and performing a photopheresis treatment | THERAKOS INC (US) | 2009-08-19 | — | — | EP | disclosed |
| EP-1951036-A4 | THE USE OF APOPTOTIC CELLS EX VIVO TO GENERATE REGULATORY T-CELLS | THERAKOS INC (US) | 2009-05-27 | — | — | EP | disclosed |
| US-7503889-B2 | Apparatus for the continuous separation of biological fluids into components and method of using same | SpecGx LLC | 2009-03-17 | — | — | US | disclosed |
| EP-1736188-B1 | Improved apparatus for the continuous separation of biological fluids into components | THERAKOS INC (US) | 2009-02-18 | — | — | EP | disclosed |
| EP-2021493-A2 | METHODS AND REAGENTS FOR DETECTING SUSCEPTIBILITY TO GRAFT VERSUS HOST DISEASE OR TRANSPLANT RELATED MORTALITY | THERAKOS, INC. (US) | 2009-02-11 | — | — | EP | disclosed |
| EP-2019590-A1 | METHODS FOR TREATING DISEASES INVOLVING STRESS-RELATED DISEASES AND CONDITIONS | THERAKOS, INC. (US) | 2009-02-04 | — | — | EP | disclosed |
| US-7479123-B2 | Method for collecting a desired blood component and performing a photopheresis treatment | THERAKOS, INC. (US) | 2009-01-20 | — | — | US | disclosed |
| US-7476209-B2 | Method and apparatus for collecting a blood component and performing a photopheresis treatment | THERAKOS, INC. (US) | 2009-01-13 | — | — | US | disclosed |
| EP-2008676-A2 | Blood separation apparatus and method of using the same | THERAKOS, INC. (US) | 2008-12-31 | — | — | EP | disclosed |
| US-7465285-B2 | Control system for driving fluids through an extracorporeal blood circuit | THERAKOS, INC. (US) | 2008-12-16 | — | — | US | disclosed |
| EP-1512420-B1 | Cassette for controlling movement of blood and separated blood components | THERAKOS INC (US) | 2008-11-19 | — | — | EP | disclosed |
| EP-1990055-A2 | Methods for pretreating a subject with extracorporeal photopheresis and/or apoptotic cells | Therakos, Inc. (US) | 2008-11-12 | — | — | EP | disclosed |
| US-20080267934-A1 | Using apoptotic peripheral blood mononuclear cells to generate lymphocytes specific to apoptotic cells; for use in treating nervous system, autoimmune, inflammatory and cell proliferative disorders | OCERA THERAPEUTICS LLC | 2008-10-30 | — | — | US | disclosed |
| EP-1951303-A2 | THERAPY WITH CD4 BINDING PEPTIDES AND RADIATION | Genmab A/S (DK) | 2008-08-06 | — | — | EP | disclosed |
| EP-1951036-A2 | THE USE OF APOPTOTIC CELLS EX VIVO TO GENERATE REGULATORY T-CELLS | THERAKOS, INC. (US) | 2008-08-06 | — | — | EP | disclosed |
| EP-1469733-A4 | METHODS FOR PRETREATING A SUBJECT WITH EXTRACORPOREAL PHOTOPHERESIS AND/OR APOPTOTIC CELLS | THERAKOS INC (US) | 2008-07-23 | — | — | EP | disclosed |
| WO-2007142769-A1 | METHODS FOR TREATING DISEASES INVOLVING STRESS-RELATED DISEASES AND CONDITIONS | THERAKOS, INC. (US) | 2007-12-13 | — | — | WO | disclosed |
| US-20070264663-A1 | Methods and reagents for detecting susceptibility to graft versus host disease or transplant related mortality | THERAKOS INC. | 2007-11-15 | — | — | US | disclosed |
| WO-2007127493-A2 | METHODS AND REAGENTS FOR DETECTING SUSCEPTIBILITY TO GRAFT VERSUS HOST DISEASE OR TRANSPLANT RELATED MORTALITY | THERAKOS, INC. (US) | 2007-11-08 | — | — | WO | disclosed |
| WO-2007055992-A2 | THE USE OF APOPTOTIC CELLS EX VIVO TO GENERATE REGULATORY T CELLS | THERAKOS INC. (US) | 2007-05-18 | — | — | WO | disclosed |
| US-20070100272-A1 | METHOD FOR COLLECTING A DESIRED BLOOD COMPONENT AND PERFORMING A PHOTOPHERESIS TREATMENT | MALLINCKRODT ENTERPRISES LLC | 2007-05-03 | — | — | US | disclosed |
| US-20070098686-A1 | Use of apoptotic cells ex vivo to generate regulatory T Cells | THERAKOS INC. | 2007-05-03 | — | — | US | disclosed |
| US-7211037-B2 | Apparatus for the continuous separation of biological fluids into components and method of using same | THERAKOS, INC. (US) | 2007-05-01 | — | — | US | disclosed |
| WO-2007019865-A2 | THERAPY WITH CD4 BINDING PEPTIDES AND RADIATION | GENMAB A/S (DK) | 2007-02-22 | — | — | WO | disclosed |
| EP-1736188-A1 | Improved apparatus for the continuous separation of biological fluids into componenets and method of using same | THERAKOS, INC. (US) | 2006-12-27 | — | — | EP | disclosed |
| EP-1512419-B1 | Improved apparatus for the continuous separation of biological fluids into components | THERAKOS INC (US) | 2006-11-15 | — | — | EP | disclosed |
| US-20060252674-A1 | Methods for pretreating a subject with extracorporeal photopheresis | THERAKOS, INC. | 2006-11-09 | — | — | US | disclosed |
| US-20060219644-A1 | Control system for driving fluids through an extracorporeal blood circuit | THERAKOS, INC. | 2006-10-05 | — | — | US | disclosed |
| US-20060224099-A1 | Control system for driving fluids through an extracorporeal blood circuit | THERAKOS, INC. | 2006-10-05 | — | — | US | disclosed |
| US-20060222561-A1 | Control system for driving fluids through an extracorporeal blood circuit | MALLINCKRODT ENTERPRISES LLC | 2006-10-05 | — | — | US | disclosed |
| US-20060217651-A1 | Control system for driving fluids through an extracorporeal blood circuit | THERAKOS, INC. | 2006-09-28 | — | — | US | disclosed |
| US-20060189469-A1 | Apparatus for the continuous separation of biological fluids into components and method of using same | MALLINCKRODT LLC | 2006-08-24 | — | — | US | disclosed |
| US-20060186061-A1 | Apparatus for the continuous separation of biological fluids into components and method of using same | MALLINCKRODT LLC | 2006-08-24 | — | — | US | disclosed |
| US-20060155236-A1 | Method and apparatus for collecting a blood component and performing a photopheresis treatment | SpecGx LLC | 2006-07-13 | — | — | US | disclosed |
| EP-1674120-A1 | Method and apparatus for collecting a blood component and performing a photopheresis treatment | THERAKOS, INC. (US) | 2006-06-28 | — | — | EP | disclosed |
| EP-1674095-A1 | Phototherapy compositions | OMJ Ireland Limited (PR) | 2006-06-28 | — | — | EP | disclosed |
| US-20060134031-A1 | Phototherapy compositions and methods | MALLINCKRODT ENTERPRISES LLC | 2006-06-22 | — | — | US | disclosed |
| EP-0994743-B1 | Treatment of inflammatory disorders of the bowel or urinary bladder | THERAKOS INC (US) | 2006-05-31 | — | — | EP | disclosed |
| EP-0910428-B1 | PHOTOPHERESIS TREATMENT OF CHRONIC HCV INFECTIONS | THERAKOS INC (US) | 2005-10-26 | — | — | EP | disclosed |
| US-20050163778-A1 | Extracorporeal photopheresis in combination with anti-TNF treatment | THEROKOS, INC. | 2005-07-28 | — | — | US | disclosed |
| EP-0935462-B1 | PHOTOPHERESIS TREATMENT OF LEUKOCYTES | THERAKOS INC (US) | 2005-07-27 | — | — | EP | disclosed |
| EP-1550454-A1 | Extracorporeal photopheresis in combination with anti-TNF treatment | THERAKOS, INC. (US) | 2005-07-06 | — | — | EP | disclosed |
| EP-1512420-A2 | Blood separation apparatus and method of using the same | THERAKOS, INC. (US) | 2005-03-09 | — | — | EP | disclosed |
| EP-1512418-A2 | Control systems for driving fluids through an extracorporeal blood circuit | THERAKOS, INC. (US) | 2005-03-09 | — | — | EP | disclosed |
| EP-1512419-A1 | Improved apparatus for the continuous separation of biological fluids into components and method of using same | THERAKOS, INC. (US) | 2005-03-09 | — | — | EP | disclosed |
| EP-1512421-A2 | Method for collecting a desired blood component and performing a photopheresis treatment | THERAKOS, INC. (US) | 2005-03-09 | — | — | EP | disclosed |
| US-20050049539-A1 | Control system for driving fluids through an extracorporeal blood circuit | O'HARA GERALD P (US) | 2005-03-03 | — | — | US | disclosed |
| WO-2004101805-A1 | METHOD FOR RECOMBINANT PRODUCTION OF MAMMALIAN PROTEINS AND PROTEINS OBTAINABLE BY SUCH METHOD | AXXIMA PHARMACEUTICALS AG (DE) | 2004-11-25 | — | — | WO | disclosed |
| EP-1477567-A1 | Method for recombinant production of mammalian proteins and proteins obtainable by such method | Axxima Pharmaceuticals AG (DE) | 2004-11-17 | — | — | EP | disclosed |
| EP-1469733-A2 | METHODS FOR PRETREATING A SUBJECT WITH EXTRACORPOREAL PHOTOPHERESIS AND/OR APOPTOTIC CELLS | Therakos, Inc. (US) | 2004-10-27 | — | — | EP | disclosed |
| US-20040143208-A1 | Irradiation chamber | GARA STEPHEN (US) | 2004-07-22 | — | — | US | disclosed |
| US-20040127841-A1 | Method for collecting a desired blood component and performing a photopheresis treatment | SpecGx LLC | 2004-07-01 | — | — | US | disclosed |
| US-20040124157-A1 | Apparatus for the continuous separation of biological fluids into components and method of using same | SpecGx LLC | 2004-07-01 | — | — | US | disclosed |
| US-20040127840-A1 | Blood separation apparatus and method of using the same | GARA STEVE (US) | 2004-07-01 | — | — | US | disclosed |
| EP-1433492-A1 | Irradiation chamber | THERAKOS, INC. (US) | 2004-06-30 | — | — | EP | disclosed |
| US-20040062754-A1 | Photopheresis treatment of chronic HCV infections | O'BRIEN CHRISTOPHER B (US) | 2004-04-01 | — | — | US | disclosed |
| US-20030157073-A1 | Methods for pretreating a subject with apoptotic cells | THERAKOS, INC. | 2003-08-21 | — | — | US | disclosed |
| US-20030139466-A1 | Methods for pretreating a subject with extracorporeal photopheresis | THERAKOS, INC. | 2003-07-24 | — | — | US | disclosed |
| WO-2003045979-A2 | METHODS FOR PRETREATING A SUBJECT WITH EXTRACORPOREAL PHOTOPHERESIS AND/OR APOPTOTIC CELLS | THERAKOS, INC. (US) | 2003-06-05 | — | — | WO | disclosed |
| US-20030035813-A1 | IMMUNOLOGICAL TREATMENT METHODS AND AGENTS | KLAINER ALBERT S (US) | 2003-02-20 | — | — | US | disclosed |
| EP-0892599-A4 | METHOD FOR REMOVAL OF PSORALENS FROM BIOLOGICAL FLUIDS | THERAKOS INC (US) | 2001-05-16 | — | — | EP | disclosed |
| US-6228995-B1 | REMOVING PSORLEN OR DEGRADATION PRODUCTS BY CONTACTING BLOOD OR BLOOD PRODUCTS WITH ABSORBENT BEADS OR FIBERS INCLUDING ION EXCHANGE RESINS, POLYSTYRENE, OR POLYSTYRENE COPOLYMERIZED WITH DIVINYLBENZENE; THEN COLLECTING BLOOD | THERAKOS, INC. | 2001-05-08 | — | — | US | disclosed |
| EP-0910428-A4 | PHOTOPHERESIS TREATMENT OF CHRONIC HCV INFECTIONS | THERAKOS INC (US) | 2001-03-28 | — | — | EP | disclosed |
| EP-0994743-A4 | TREATMENT OF INFLAMMATORY DISORDERS OF THE BOWEL AND URINARY BLADDER | THERAKOS INC (US) | 2001-02-14 | — | — | EP | disclosed |
| EP-0994743-A1 | TREATMENT OF INFLAMMATORY DISORDERS OF THE BOWEL AND URINARY BLADDER | THERAKOS, INC. (US) | 2000-04-26 | — | — | EP | disclosed |
| US-5985914-A | ANTIINFLAMMATORY AGENTS | THERAKOS, INC. (US) | 1999-11-16 | — | — | US | disclosed |
| US-5984887-A | Photopheresis treatment of leukocytes | THERAKOS, INC. (US) | 1999-11-16 | — | — | US | disclosed |
| EP-0579784-B1 | METHOD FOR PREVENTING RESTENOSIS FOLLOWING RECONFIGURATION OF BODY VESSELS | ADVANCED RES & TECH INST (US) | 1999-11-10 | — | — | EP | disclosed |
| EP-0910428-A1 | PHOTOPHERESIS TREATMENT OF CHRONIC HCV INFECTIONS | THERAKOS, INC. (US) | 1999-04-28 | — | — | EP | disclosed |
| EP-0661920-B1 | THE USE OF PSORALEN COMPOUNDS TO INHIBIT RESTENOSIS FOLLOWING ANGIOPLASTY | BISACCIA EMIL (US) | 1999-04-14 | — | — | EP | disclosed |
| EP-0892599-A1 | METHOD FOR REMOVAL OF PSORALENS FROM BIOLOGICAL FLUIDS | THERAKOS, INC. (US) | 1999-01-27 | — | — | EP | disclosed |
| WO-1999002215-A1 | TREATMENT OF INFLAMMATORY DISORDERS OF THE BOWEL AND URINARY BLADDER | THERAKOS, INC. (US) | 1999-01-21 | — | — | WO | disclosed |
| WO-1997036581-A9 | PHOTOPHERESIS TREATMENT OF LEUKOCYTES | — | 1997-12-04 | — | — | WO | disclosed |
| WO-1997037654-A1 | USE OF PHOTOPHERESIS IN THE TREATMENT OF CHRONIC INFECTION BY HEPATITIS C VIRUS | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 1997-10-16 | — | — | WO | disclosed |
| WO-1997037536-A1 | METHOD FOR REMOVAL OF PSORALENS FROM BIOLOGICAL FLUIDS | THERAKOS, INC. (US) | 1997-10-16 | — | — | WO | disclosed |
| WO-1997036634-A1 | PHOTOPHERESIS TREATMENT OF CHRONIC HCV INFECTIONS | THERAKOS, INC. (US) | 1997-10-09 | — | — | WO | disclosed |
| EP-0661920-A1 | THE USE OF PSORALEN COMPOUNDS TO INHIBIT RESTENOSIS FOLLOWING ANGIOPLASTY | BISACCIA, Emil (US) | 1995-07-12 | — | — | EP | disclosed |
| US-5426116-A | Photophoresis methods for treating atherosclerosis and for preventing restenosis following angioplasty | BISACCIA & KLAINER, INC. (US) | 1995-06-20 | — | — | US | disclosed |
| EP-0661920-A4 | THE USE OF PSORALEN COMPOUNDS TO INHIBIT RESTENOSIS FOLLOWING ANGIOPLASTY. | BISACCIA EMIL (US) | 1995-03-02 | — | — | EP | disclosed |
| WO-1994013282-A1 | TREATMENT OF LYMES DISEASE AND ASSOCIATED DEBILITATING CONDITIONS | BISACCIA EMIL (US) | 1994-06-23 | — | — | WO | disclosed |
| EP-0579784-A4 | — | — | 1994-04-06 | — | — | EP | disclosed |
| US-5284869-A | Photophoresis methods for treating atherosclerosis and for preventing restenosis following angioplasty | BISACCIA & KLAINER, INC. | 1994-02-08 | — | — | US | disclosed |
| EP-0579784-A1 | METHOD FOR PREVENTING RESTENOSIS FOLLOWING RECONFIGURATION OF BODY VESSELS | INDIANA UNIVERSITY FOUNDATION (US) | 1994-01-26 | — | — | EP | disclosed |
| WO-1993011657-A2 | THE USE OF PSORALEN COMPOUNDS TO INHIBIT RESTENOSIS FOLLOWING ANGIOPLASTY | BISACCIA EMIL (US) | 1993-06-24 | — | — | WO | disclosed |
| US-5219882-A | Treatment methods for lymes disease and associated debilitating conditions | BISACCIA EMIL (US) | 1993-06-15 | — | — | US | disclosed |
| US-5176921-A | Addition of a psoralen and irradiation | DIAMOND SCIENTIFIC CO. (US) | 1993-01-05 | — | — | US | disclosed |
| WO-1992018122-A1 | METHOD FOR PREVENTING RESTENOSIS FOLLOWING RECONFIGURATION OF BODY VESSELS | INDIANA UNIVERSITY FOUNDATION (US) | 1992-10-29 | — | — | WO | disclosed |
| EP-0453497-A4 | TREATMENT METHODS AND VACCINES | — | 1992-10-07 | — | — | EP | disclosed |
| EP-0506147-A2 | Canine distemper virus vaccine | DIAMOND SCIENTIFIC CO. (US) | 1992-09-30 | — | — | EP | disclosed |
| US-5116864-A | Method for preventing restenosis following reconfiguration of body vessels | INDIANA UNIVERSITY FOUNDATION (US) | 1992-05-26 | — | — | US | disclosed |
| US-5106619-A | Prepared by psoralen inactivation in non-oxidizing atmosphere | DIAMOND SCIENTIFIC CO. (US) | 1992-04-21 | — | — | US | disclosed |
| EP-0453497-A1 | TREATMENT METHODS AND VACCINES | BISACCIA, Emil (US) | 1991-10-30 | — | — | EP | disclosed |
| US-5000951-A | Multivalent canine distemper virus vaccine | DIAMOND SCIENTIFIC COMPANY (US) | 1991-03-19 | — | — | US | disclosed |
| US-4992272-A | Inactivated virus which retains immunogenicity | DIAMOND SCIENTIFIC (US) | 1991-02-12 | — | — | US | disclosed |
| EP-0124363-B1 | PHOTOCHEMICAL DECONTAMINATION TREATMENT OF WHOLE BLOOD OR BLOOD COMPONENTS | DIAMOND SCIENTIFIC CO. (US) | 1990-12-19 | — | — | EP | disclosed |
| US-4960408-A | ADMINISTERING A PSORALEN COMPOUND, EXPOSING TO ELECTROMAGNETIC RADIATION | KLAINER ALBERT S (US) | 1990-10-02 | — | — | US | disclosed |
| WO-1990007952-A1 | TREATMENT METHODS AND VACCINES | BISACCIA EMIL (US) | 1990-07-26 | — | — | WO | disclosed |
| US-4791062-A | FELINE VIRAL RHINOTRACHEITIS; FUROCOUMARIN INACTIVATED FELINE HERPES VIRUS I | DIAMOND SCIENTIFIC CO. (US) | 1988-12-13 | — | — | US | disclosed |
| EP-0282179-A2 | Canine distemper virus vaccine | Bayer Corporation (US) | 1988-09-14 | — | — | EP | disclosed |
| US-4748120-A | Photochemical decontamination treatment of whole blood or blood components | DIAMOND SCIENTIFIC CO. (US) | 1988-05-31 | — | — | US | disclosed |
| US-4727027-A | FUROCOUMARIN DERIVATIVE AND ULTRAVIOLET IRRADIATION | DIAMOND SCIENTIFIC CO. (US) | 1988-02-23 | — | — | US | disclosed |
| US-4693981-A | ULTRAVIOLET RADIATION AND FUROCOUMARIN | ADVANCED GENETICS RESEARCH INSTITUTE (US) | 1987-09-15 | — | — | US | disclosed |
| US-4556556-A | ULTRAVIOLET INACTIVATION IN THE PRESENCE OF A FUROCOUMARIN COMPOUND | ADVANCED GENETICS RESEARCH INSTITUTE (US) | 1985-12-03 | — | — | US | disclosed |
| US-4545987-A | Psoralen inactivated double-stranded RNA viral vaccines | ADVANCED GENETICS RESEARCH INSTITUTE (US) | 1985-10-08 | — | — | US | disclosed |
| EP-0030358-B1 | APPARATUS FOR REDUCING THE FUNCTIONING LYMPHOCYTE POPULATION IN BLOOD | LEUKOCYTE RESEARCH, INC. (US) | 1985-03-27 | — | — | EP | disclosed |
| EP-0124363-A2 | Photochemical decontamination treatment of whole blood or blood components | DIAMOND SCIENTIFIC CO. (US) | 1984-11-07 | — | — | EP | disclosed |
| US-4321919-A | Method and system for externally treating human blood | LEUKOCYTE RESEARCH, INC. (US) | 1982-03-30 | — | — | US | disclosed |
| EP-0030358-A2 | Apparatus for reducing the functioning lymphocyte population in blood | LEUKOCYTE RESEARCH, INC. (US) | 1981-06-17 | — | — | EP | disclosed |
| EP-0030358-A2 | Apparatus for reducing the functioning lymphocyte population in blood | LEUKOCYTE RESEARCH, INC. (US) | 1981-06-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060134031-A1 | Phototherapy compositions and methods | VCL, TYR, TTPA | KDM4E 4478/4885ALDH1A1 1344/4885HSD17B10 3734/4885 |
| US-20100015134-A1 | Therapy With CD4 Binding Peptides and Radiation | CD4, CD74, SELPLG | KDM4E 4522/4885ALDH1A1 4414/4885HSD17B10 4747/4885 |
| US-20120039825-A1 | PHOTOTHERAPY COMPOSITIONS AND METHODS | VCL, TYR, TTPA | KDM4E 4478/4885ALDH1A1 1344/4885HSD17B10 3734/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.